PDCD1 and cancer: Mechanistically, malignant tumors may have the ability to stimulate the expression of various immune checkpoints, such as PD-1 and PD-L1, thereby inhibiting the normal activation of T cells within the tumor microenvironment (TME), which ultimately allows the tumor to escape immune attack.